Published October 26, 2021 | Version v1
Journal article Open

Glucose 6-P dehydrogenase delays the onset of frailty by protecting against muscle damage

  • 1. Freshage Research Group, Department of Physiology, School of Medicine, University of Valencia, CIBERFES, Fundación Investigación Hospital Clínico Universitario/INCLIVA, Valencia, Spain
  • 2. Freshage Research Group, Department of Physiology, School of Medicine, University of Valencia, CIBERFES, Fundación Investigación Hospital Clínico Universitario/INCLIVA, Valencia, Spain - Department of Integrative Biology, University of California, Berkeley, CA, USA
  • 3. INRAE, UMR866 Dynamique Musculaire et Métabolisme, Université de Montpellier, Montpellier, France
  • 4. Metabolic Syndrome Group - BIOPROMET, Madrid Institute for Advanced Studies - IMDEA Food, CEI UAM+CSIC, Madrid, Spain
  • 5. Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain - Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain
  • 6. Department of Experimental and Health Sciences, University Pompeu Fabra and CIBERNED, Barcelona, Spain
  • 7. Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain - Department of Experimental and Health Sciences, University Pompeu Fabra and CIBERNED, Barcelona, Spain - Spanish National Center on Cardiovascular Research (CNIC), Madrid, Spain
  • 8. Clinica Ypsilon de medicina física y rehabilitación, Valencia, Spain

Description

Abstract

Background

Frailty is a major age-associated syndrome leading to disability. Oxidative damage plays a significant role in the promotion of frailty. The cellular antioxidant system relies on reduced nicotinamide adenine dinucleotide phosphate (NADPH) that is highly dependent on glucose 6-P dehydrogenase (G6PD). The G6PD-overexpressing mouse (G6PD-Tg) is protected against metabolic stresses. Our aim was to examine whether this protection delays frailty.

Methods

Old wild-type (WT) and G6PD-Tg mice were evaluated longitudinally in terms of frailty. Indirect calorimetry, transcriptomic profile, and different skeletal muscle quality markers and muscle regenerative capacity were also investigated.

Results

The percentage of frail mice was significantly lower in the G6PD-Tg than in the WT genotype, especially in 26-month-old mice where 50% of the WT were frail vs. only 13% of the Tg ones (P < 0.001). Skeletal muscle transcriptomic analysis showed an up-regulation of respiratory chain and oxidative phosphorylation (P = 0.009) as well as glutathione metabolism (P = 0.035) pathways in the G6PD-Tg mice. Accordingly, the Tg animals exhibited an increase in reduced glutathione (34.5%, P < 0.01) and a decrease on its oxidized form (−69%, P < 0.05) and in lipid peroxidation (4-HNE: −20.5%, P < 0.05). The G6PD-Tg mice also showed reduced apoptosis (BAX/Bcl2: −25.5%, P < 0.05; and Bcl-xL: −20.5%, P < 0.05), lower levels of the intramuscular adipocyte marker FABP4 (−54.7%, P < 0.05), and increased markers of mitochondrial content (COX IV: 89.7%, P < 0.05; Grp75: 37.8%, P < 0.05) and mitochondrial OXPHOS complexes (CII: 81.25%, P < 0.01; CIII: 52.5%, P < 0.01; and CV: 37.2%, P < 0.05). Energy expenditure (−4.29%, P < 0.001) and the respiratory exchange ratio were lower (−13.4%, P < 0.0001) while the locomotor activity was higher (43.4%, P < 0.0001) in the 20-month-old Tg, indicating a major energetic advantage in these mice. Short-term exercise training in young C57BL76J mice induced a robust activation of G6PD in skeletal muscle (203.4%, P < 0.05), similar to that achieved in the G6PD-Tg mice (142.3%, P < 0.01).

Conclusions

Glucose 6-P dehydrogenase deficiency can be an underestimated risk factor for several human pathologies and even frailty. By overexpressing G6PD, we provide the first molecular model of robustness. Because G6PD is regulated by pharmacological and physiological interventions like exercise, our results provide molecular bases for interventions that by increasing G6PD will delay the onset of frailty.

 

Files

Arc-Chagnaud et al .pdf

Files (36.1 MB)

Name Size Download all
md5:78a7b378958c0485288d3514db8b1db7
36.1 MB Preview Download

Additional details

Funding

DIABFRAIL-LATAM – Scaling-up of and evidence-based intervention programme in older people with Diabetes and Frailty in LatinAmerica 825546
European Commission
ERA-HDHL – ERA-NET Biomarkers for Nutrition and Health implementing the JPI HDHL objectives 696295
European Commission
UPGRADE – Unlocking Precision Gene Therapy 825825
European Commission